The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 04, 2013
Filed:
Nov. 22, 2010
Atsuro Nakazato, Tokyo, JP;
Taketoshi Okubo, Tokyo, JP;
Dai Nozawa, Tokyo, JP;
Mikako Yamaguchi, Tokyo, JP;
Tomoko Tamita, Tokyo, JP;
Ludo E. J. Kennis, Beerse, BE;
Marcel F. L. DE Bruyn, Beerse, BE;
Jean-pierre A. M. Bongartz, Beerse, BE;
Frans M. A. Van Den Keybus, Beerse, BE;
Yves E. M. Van Roosbroeck, Beerse, BE;
Marcel G. M. Luyckx, Beerse, BE;
Robert J. M. Hendrickx, Beerse, BE;
Atsuro Nakazato, Tokyo, JP;
Taketoshi Okubo, Tokyo, JP;
Dai Nozawa, Tokyo, JP;
Mikako Yamaguchi, Tokyo, JP;
Tomoko Tamita, Tokyo, JP;
Ludo E. J. Kennis, Beerse, BE;
Marcel F. L. De Bruyn, Beerse, BE;
Jean-Pierre A. M. Bongartz, Beerse, BE;
Frans M. A. Van Den Keybus, Beerse, BE;
Yves E. M. Van Roosbroeck, Beerse, BE;
Marcel G. M. Luyckx, Beerse, BE;
Robert J. M. Hendrickx, Beerse, BE;
Taisho Pharmaceutical Co., Ltd., Tokyo, JP;
Abstract
An object of the present invention is to provide an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastric diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alopecia, irritable bowel syndrome, sleep disorders, epilepsy, dermatitides, schizophrenia, etc. This problem can be solved with a pyrrolopyrimidine or pyrrolopyridine derivative substituted with a cyclic amino group represented by formula [I] below which has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved.